Patent classifications
A61K31/43
Nasal composition comprising a mucoadhesive polymer
The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.
Nasal composition comprising a mucoadhesive polymer
The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.
Nasal composition comprising a mucoadhesive polymer
The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.
COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
Compositions and methods of potentiating antimicrobials
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
Compositions and methods of potentiating antimicrobials
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
Compositions and methods of potentiating antimicrobials
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
Therapeutic methods and combinations
Combinations comprising substituted 1-hydroxypyridine-2(1H)-thiones or a pharmaceutically acceptable salt thereof and an antibacterial agent are disclosed. Also disclosed are therapeutic methods comprising the administration of a substituted 1-hydroxypyridine-2(1H)-thione or a pharmaceutically acceptable salt thereof and an antibacterial agent.